Earnings ·
Protalix reports $75.6M YTD revenue and $4.0M Q3 net income
PLXProtalix BioTherapeutics, Inc.
Protalix BioTherapeutics reported third-quarter 2026 financial results showing total revenues of $21.9 million, up from $17.9 million in the prior-year period, driven by higher sales to partner Chiesi and a $25.0 million milestone payment received in Q1. Net income for the quarter was $4.0 million ($0.05 per share), compared to $2.4 million ($0.03 per share) in 2025. Year-to-date revenues reached $75.6 million, with net income of $26.1 million. The company reaffirmed its full-year revenue guidance of approximately $78.0 million to $83.0 million and reported cash and short-term deposits of $48.5 million as of September 30, 2026. Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases.